{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T03:57:51Z","timestamp":1794887871114,"version":"4.9.1"},"reference-count":30,"publisher":"American Association for Cancer Research (AACR)","issue":"9","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>The BRAF inhibitor encorafenib (Enco) plus the anti-EGFR antibody cetuximab (Cetux) improved overall survival, objective response rate, and progression-free survival in previously treated BRAFV600E-mutant metastatic colorectal cancer in BEACON, a phase III randomized trial, leading to regulatory approval for this indication. To support rapid, plasma-based testing for BRAFV600E identification, clinical validity of a ctDNA-based assay, FoundationOneLiquid CDx (F1LCDx), was assessed against the reference tumor-based clinical trial assay (CTA) in liquid biopsy\u2013evaluable samples from BEACON and commercially obtained tissue-matched plasma samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>Pretreatment tissue samples were collected in BEACON to confirm BRAF mutational status using the central single gene PCR assay. Concordance between the CTA and liquid biopsy tests was assessed, and clinical validity of liquid biopsy testing was examined using clinical outcomes from BEACON.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of the 523 evaluable patients, 433 with matched tissue and plasma samples had CTA and F1LCDx results available (BEACON, n = 328; commercial, n = 105). A strong concordance in detecting BRAFV600E was found between F1LCDx and CTA, with a positive percent agreement of 87.2% and negative percent agreement of 97.1%. Among 42 F1LCDx\u2212\/CTA+ samples, 41 (97.6%) had ctDNA tumor fraction &amp;lt;1%. Among samples with ctDNA tumor fraction &amp;gt;1%, the positive percent agreement was 99.4% and negative percent agreement was 86.7%. Clinical outcomes with Enco plus Cetux were similar between those identified as F1LCDx+\/CTA+ and CTA+ overall.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This study supports using liquid biopsies as a clinically valid assay for identifying BRAFV600E alterations in patients with metastatic colorectal cancer, particularly when ctDNA tumor fraction was &amp;gt;1%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>In the phase III BEACON trial, which established Enco plus Cetux as a standard of care for previously treated BRAFV600E-mutant metastatic colorectal cancer, mutational status was confirmed through testing of tumor tissue. To support rapid, less invasive testing for BRAFV600E in plasma, this retrospective study assessed a ctDNA-based assay and found strong concordance between the liquid biopsy test and the tumor-based assay in detecting BRAFV600E.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0002","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T11:36:36Z","timestamp":1755689796000},"page":"1566-1573","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical Validity of FoundationOne Liquid CDx for Detection of\n                    <i>BRAF<\/i>\n                    V600E in Colorectal Cancer"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7233-5454","authenticated-orcid":false,"given":"Rona","family":"Yaeger","sequence":"first","affiliation":[{"name":"1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8570-1401","authenticated-orcid":false,"given":"Jean-Fran\u00e7ois","family":"Martini","sequence":"additional","affiliation":[{"name":"2Translational Science Operations, Pfizer, Inc., La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5461-9777","authenticated-orcid":false,"given":"Lincoln","family":"Pasquina","sequence":"additional","affiliation":[{"name":"3Clinical Development, Foundation Medicine Inc., Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9897-2806","authenticated-orcid":false,"given":"Brian","family":"Tunquist","sequence":"additional","affiliation":[{"name":"4Formerly Pfizer, Inc., New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2415-5355","authenticated-orcid":false,"given":"Xiaosong","family":"Zhang","sequence":"additional","affiliation":[{"name":"5Global Development, Pfizer, Inc., South San Francisco, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4061-3701","authenticated-orcid":false,"given":"Fatima","family":"Kaiser","sequence":"additional","affiliation":[{"name":"6Formerly Foundation Medicine Inc., Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8614-5216","authenticated-orcid":false,"given":"Norberto","family":"Pantoja Galicia","sequence":"additional","affiliation":[{"name":"7Biometrics, Foundation Medicine Inc., Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2867-263X","authenticated-orcid":false,"given":"Shibing","family":"Deng","sequence":"additional","affiliation":[{"name":"2Translational Science Operations, Pfizer, Inc., La Jolla, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8012-9551","authenticated-orcid":false,"given":"Siliang","family":"Gong","sequence":"additional","affiliation":[{"name":"6Formerly Foundation Medicine Inc., Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3297-119X","authenticated-orcid":false,"given":"Cui","family":"Guo","sequence":"additional","affiliation":[{"name":"7Biometrics, Foundation Medicine Inc., Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3310-0837","authenticated-orcid":false,"given":"Jimmy","family":"Kiely","sequence":"additional","affiliation":[{"name":"7Biometrics, Foundation Medicine Inc., Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1446-5864","authenticated-orcid":false,"given":"Ta-Chou Vincent","family":"Ng","sequence":"additional","affiliation":[{"name":"7Biometrics, Foundation Medicine Inc., Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1760-4697","authenticated-orcid":false,"given":"Graham","family":"Ferrier","sequence":"additional","affiliation":[{"name":"8Global Medical, Pfizer, Inc., New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2495-8139","authenticated-orcid":false,"given":"Josep","family":"Tabernero","sequence":"additional","affiliation":[{"name":"9Department of Medical Oncology, Vall d\u2019Hebron Hospital Campus and Vall d\u2019Hebron Institute of Oncology (VHIO), University of Vic \u2013 Central University of Catalonia, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9647-3416","authenticated-orcid":false,"given":"Scott","family":"Kopetz","sequence":"additional","affiliation":[{"name":"10Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"2025090903184833000_bib1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","article-title":"Liquid biopsy: current technology and clinical applications","volume":"15","author":"Nikanjam","year":"2022","journal-title":"J Hematol Oncol"},{"key":"2025090903184833000_bib2","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/cyt.13295","article-title":"Circulating tumour DNA testing in metastatic breast cancer: integration with tissue testing","volume":"34","author":"Ranghiero","year":"2023","journal-title":"Cytopathology"},{"key":"2025090903184833000_bib3","doi-asserted-by":"crossref","first-page":"48832","DOI":"10.18632\/oncotarget.9453","article-title":"Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer","volume":"7","author":"Cheng","year":"2016","journal-title":"Oncotarget"},{"key":"2025090903184833000_bib4","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-020-1063-5","article-title":"Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies","volume":"26","author":"Nakamura","year":"2020","journal-title":"Nat Med"},{"key":"2025090903184833000_bib5","doi-asserted-by":"crossref","first-page":"e005344","DOI":"10.1136\/jitc-2022-005344","article-title":"Regulatory implications of ctDNA in immuno-oncology for solid tumors","volume":"11","author":"Vellanki","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2025090903184833000_bib6","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.3390\/cancers12061376","article-title":"Liquid biopsy in colorectal carcinoma: clinical applications and challenges","volume":"12","author":"Kolen\u010d\u00edk","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025090903184833000_bib7","doi-asserted-by":"crossref","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"key":"2025090903184833000_bib8","doi-asserted-by":"crossref","first-page":"e2200694","DOI":"10.1200\/PO.22.00694","article-title":"Dynamic monitoring of circulating tumor DNA in patients with metastatic colorectal cancer","volume":"7","author":"Urbini","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"2025090903184833000_bib9","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.3390\/cancers14133275","article-title":"Circulating tumor DNA-based genomic profiling assays in adult solid tumors for precision oncology: recent advancements and future challenges","volume":"14","author":"Chan","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025090903184833000_bib10","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N Engl J Med"},{"key":"2025090903184833000_bib11","article-title":"QIAGEN launches therascreen BRAF test as companion diagnostic to a BRAFTOVI\u00ae (encorafenib) based regimen in metastatic colorectal cancer","author":"QIAGEN"},{"key":"2025090903184833000_bib12","doi-asserted-by":"crossref","first-page":"e0237802","DOI":"10.1371\/journal.pone.0237802","article-title":"Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin","volume":"15","author":"Woodhouse","year":"2020","journal-title":"PLoS One"},{"key":"2025090903184833000_bib13","article-title":"FDA approves FoundationOne liquid CDx as CDx for Pfizer\u2019s Braftovi combo in mCRC","author":"NS Medical Devices"},{"key":"2025090903184833000_bib14","article-title":"therascreen\u00ae BRAF V600E RGQ PCR Kit instructions for use (Handbook)","author":"QIAGEN"},{"key":"2025090903184833000_bib15","article-title":"Foundation Medicine Inc. FoundationOne\u00aeCDx technical information"},{"key":"2025090903184833000_bib16","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1158\/1078-0432.CCR-23-3321","article-title":"Measurement of ctDNA tumor fraction identifies informative negative liquid biopsy results and informs value of tissue confirmation","volume":"30","author":"Rolfo","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"Suppl 6","key":"2025090903184833000_bib17","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1158\/1538-7445.AM2024-971","article-title":"Abstract 971: validation of a tumor-na\u00efve circulating tumor DNA (ctDNA) response monitoring panel in advanced non-small cell lung cancer (aNSCLC)","volume":"84","author":"Chiang","year":"2024","journal-title":"Cancer Res"},{"key":"2025090903184833000_bib18","doi-asserted-by":"crossref","first-page":"e2351700","DOI":"10.1001\/jamanetworkopen.2023.51700","article-title":"Concurrent tissue and circulating tumor DNA molecular profiling to detect guideline-based targeted mutations in a multicancer cohort","volume":"7","author":"Iams","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2025090903184833000_bib19","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/2211-5463.13957","article-title":"Real-world genomic landscape of colon and rectal cancer","volume":"15","author":"Schulze","year":"2025","journal-title":"FEBS Open Bio"},{"key":"2025090903184833000_bib20","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1038\/s41591-024-03235-9","article-title":"Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial","volume":"30","author":"Kopetz","year":"2024","journal-title":"Nat Med"},{"key":"2025090903184833000_bib21","doi-asserted-by":"crossref","first-page":"13610","DOI":"10.3390\/ijms241713610","article-title":"ALK, ROS1, RET and NTRK1-3 gene fusions in colorectal and non-colorectal microsatellite-unstable cancers","volume":"24","author":"Mulkidjan","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025090903184833000_bib22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41698-021-00206-y","article-title":"Genomic context of NTRK1\/2\/3 fusion-positive tumours from a large real-world population","volume":"5","author":"Westphalen","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"2025090903184833000_bib23","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/s41559-021-01470-8","article-title":"Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer","volume":"5","author":"Woolston","year":"2021","journal-title":"Nat Ecol Evol"},{"key":"2025090903184833000_bib24","doi-asserted-by":"crossref","first-page":"684","DOI":"10.21037\/gs-24-115","article-title":"Baseline circulating tumor DNA predicts long-term survival outcomes for patients with early breast cancer","volume":"13","author":"Zhang","year":"2024","journal-title":"Gland Surg"},{"key":"2025090903184833000_bib25","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1158\/1078-0432.CCR-23-0956","article-title":"Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive\/HER2-negative metastatic breast cancer patients","volume":"29","author":"Pascual","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025090903184833000_bib26","doi-asserted-by":"crossref","first-page":"269","DOI":"10.21037\/tlcr.2020.03.17","article-title":"Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort","volume":"9","author":"Song","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"2025090903184833000_bib27","doi-asserted-by":"crossref","first-page":"6660571","DOI":"10.1155\/2021\/6660571","article-title":"Prognostic value of ctDNA mutation in melanoma: a meta-analysis","volume":"2021","author":"Zheng","year":"2021","journal-title":"J Oncol"},{"issue":"Suppl 16","key":"2025090903184833000_bib28","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1200\/JCO.2023.41.16_suppl.3030","article-title":"Changes in ctDNA levels as an early indicator of outcomes in advanced NSCLC treated with TKI: initial findings from a retrospective aggregate analysis of 8 clinical trials","volume":"41","author":"Stires","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025090903184833000_bib29","doi-asserted-by":"crossref","first-page":"107282","DOI":"10.1016\/j.lungcan.2023.107282","article-title":"Comparative analysis of genomic profiles between tissue-based and plasma-based next-generation sequencing in patients with non-small cell lung cancer","volume":"182","author":"Lin","year":"2023","journal-title":"Lung Cancer"},{"key":"2025090903184833000_bib30","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.31557\/APJCP.2023.24.10.3467","article-title":"Non-small cell lung cancer: targetable variants in concurrent tissue and liquid biopsy testing in a North Indian cohort","volume":"24","author":"Paturu","year":"2023","journal-title":"Asian Pac J Cancer Prev"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0002\/3642883\/crc-25-0002.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/9\/1566\/3649475\/crc-25-0002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/9\/1566\/3649475\/crc-25-0002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T07:18:55Z","timestamp":1757402335000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/9\/1566\/764558\/Clinical-Validity-of-FoundationOne-Liquid-CDx-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0002","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.30083886","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30083895","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30083871","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30083892","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30083880","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30083907","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30083868","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30083889","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30083877","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30083910","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30083901","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30083904","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8024382","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}